HomeCompareMNILY vs JNJ

MNILY vs JNJ: Dividend Comparison 2026

MNILY yields 3.16% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MNILY wins by $532.50M in total portfolio value
10 years
MNILY
MNILY
● Live price
3.16%
Share price
$16.00
Annual div
$0.50
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$532.53M
Annual income
$501,966,698.88
Full MNILY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — MNILY vs JNJ

📍 MNILY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMNILYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MNILY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MNILY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MNILY
Annual income on $10K today (after 15% tax)
$268.18/yr
After 10yr DRIP, annual income (after tax)
$426,671,694.05/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, MNILY beats the other by $426,667,708.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MNILY + JNJ for your $10,000?

MNILY: 50%JNJ: 50%
100% JNJ50/50100% MNILY
Portfolio after 10yr
$266.28M
Annual income
$250,985,694.14/yr
Blended yield
94.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MNILY
No analyst data
Altman Z
0.8
Piotroski
6/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MNILY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMNILYJNJ
Forward yield3.16%2.13%
Annual dividend / share$0.50$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$532.53M$30.3K
Annual income after 10y$501,966,698.88$4,689.40
Total dividends collected$530.28M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MNILY vs JNJ ($10,000, DRIP)

YearMNILY PortfolioMNILY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,331$631.01$10,592$272.30+$739.00MNILY
2$13,461$1,336.45$11,289$357.73+$2.2KMNILY
3$17,370$2,967.54$12,123$472.89+$5.2KMNILY
4$25,744$7,157.92$13,141$629.86+$12.6KMNILY
5$47,375$19,829.11$14,408$846.81+$33.0KMNILY
6$118,898$68,206.00$16,021$1,151.60+$102.9KMNILY
7$447,176$319,955.03$18,122$1,588.22+$429.1KMNILY
8$2,727,738$2,249,259.78$20,930$2,228.20+$2.71MMNILY
9$28,564,129$25,645,449.41$24,792$3,191.91+$28.54MMNILY
10$532,530,317$501,966,698.88$30,274$4,689.40+$532.50MMNILY

MNILY vs JNJ: Complete Analysis 2026

MNILYStock

Minor International Public Company Limited, together with its subsidiaries, operates as a hospitality, restaurant, and lifestyle company in Thailand, China, Australia, and internationally. It operates in four segments: Hotel, Mixed use, Restaurant, and Retail. As of December 31, 2021, the company had approximately 2,389 restaurant outlets in 23 countries under The Pizza Company, The Coffee Club, Riverside, Benihana, Thai Express, Bonchon, Swensen's, Sizzler, Dairy Queen, and Burger King brands. It also invested in, owned, and operated a portfolio of 520 hotels and serviced suites under the Anantara, Avani, Oaks, Tivoli, NH Collection, NH Hotels, nhow, Elewana Collection, Four Seasons, St. Regis, JW Marriott, Radisson Blu, and Minor International brands in 56 countries across the Asia Pacific, the Middle East, Africa, the Indian Ocean, Europe, and the Americas. In addition, the company distributes fashion and lifestyle products under the Anello, Bodum, Bossini, Charles & Keith, Esprit, Joseph Joseph, OVS, Radley, Zwilling J.A. Henckels, and Minor Smart Kids brands through approximately 386 retail points of sale; and provides online shopping and contract manufacturing services. Further, it is involved in the shopping mall, food and beverage sale, spa, supply chain management, distribution, management, vacation club point sale, entertainment, franchise, marketing, consulting, tour operation, asset management, airport lounge, and healthcare businesses; property investment, development, and sales activities; operation of business school; and manufacture and sale of cheese and ice-cream. The company was formerly known as Royal Garden Resorts Plc. and changed its name to Minor International Public Company Limited in 2005. Minor International Public Company Limited was founded in 1978 and is headquartered in Bangkok, Thailand.

Full MNILY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MNILY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MNILY vs SCHDMNILY vs JEPIMNILY vs OMNILY vs KOMNILY vs MAINMNILY vs ABBVMNILY vs MRKMNILY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.